(Date:10/3/2008)...KJAVIK, Iceland, Oct. 3 /- ...he filing of an investigational new drug,(IND) app...cule modulator,of phosphodiesterase 4 (PDE4), with...mpound is being developed as a new and potentially...ss and cognitive deficits associated,with Alzheime...
(Date:10/2/2008)...Study Will Compare the Results of Rosetta Genomics... Differentiates Squamous From non Squamous no...Methods, A Test Based on the miRview(TM) Technolog...bia University,s High Complexity Molecular Patholo..., Rosetta Genomics is Expecting to Launch miRview...
(Date:10/2/2008)...EBORG, Sweden, October 2 /- Calabar A...e study in xerostomia ("dry mouth"),patients has b...ied in 45,dry mouth patients between the ages of 2... dose for evaluation in a succeeding Phase III eff... cholinesterase inhibitor,physostigmine. It is adm...
(Date:10/2/2008)...ata Indicate Dual Modes of Action and Synergy with...ll/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin ...ical,studies on Angiolix showing that by blocking ...effect as well as a direct anti-proliferative effe...human breast cancer (MX-1),Angiolix had a signifi...
Breaking Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3New Legislation Would Expedite Medicare Patient Access to Physical Therapy 16169 1New Legislation Would Expedite Medicare Patient Access to Physical Therapy 16169 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 1MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 3MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 4Too Little Sleep Leads to Too Much Weight for Kids 16166 1Too Little Sleep Leads to Too Much Weight for Kids 16166 2Too Little Sleep Leads to Too Much Weight for Kids 16166 3Too Little Sleep Leads to Too Much Weight for Kids 16166 4New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 1New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 2New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 3...h Concentrations Reached in Key Lung Compartments,...RNewswire-FirstCall/ -- Arpida Ltd. today announce... AR-709. These radiolabelled,Human Microdose studi... , This groundbreaking study is the first ever usi...ntrations in lung compartments.,The results showed...
...vey Shows 89% of Patients Prefer Orapred ODT Over ...e/ -- Alliant,Pharmaceuticals announced today surv...T(TM) (Prednisolone sodium phosphate,orally disint...esults of the patient feedback survey involving mo...70) of the children,preferred Orapred ODT over liq...
Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3(Date:10/6/2008)...recently posted detailed information on its Cimzia...ous side effects caused by the drug and its family...al side effects are the development of fatal infec...d child patients. , Denve...mber one resource for everything and anything lega...
(Date:10/6/2008)...f women suffer with symptoms of menopause as House...plan. But the effects of our current economic cris...singly difficult for U.S. women to cope with the c...s new cost effective drug-free guidelines to help ... , Las Vegas, NV (PRWEB) ...
(Date:10/6/2008)...fers up to 50 percent savings on medical services ... Belleville, Ill. (Vocus) October 6, 2008 -- Alls....allsup.com/Health-Discount-Program.aspx/?=PRJ2 [H...rogram] to help millions of people with disabiliti...l services. The program is among the new financial...
(Date:10/6/2008)...swire-FirstCall/ -- SAP AG (NYSE: SAP ),today ann...r vice president,of the Healthcare industry busine...8, Mr. Papandrea will help drive SAP,s industry le...olutions to healthcare,organizations around the wo... the 3rd annual Ambassadors Dinner and the U.S.-EU...
Breaking Medicine News(10 mins):Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 3Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3...that suppresses the immune system may slow the pro...al trial of 10 people aged 8 to 35 years with type...fied antibody.// A 14-day course of the drug appea... insulin production commonly seen in type 1 diabet...
...emarkable for its ability to live in the strong ac...broccoli is powerful against the bacterium that is...r.// It's now well established that this microbe i...r. Clearing it with antibiotics is an important fo...
...d for facial cosmetic surgery has increased, so to...s never been more popular. Most products go down i...rs in Texas have looked at how cosmetic surgery, a...marketplace over the last decade. They surveyed 1...
... to acquire the cardiovascular stent business of B... in cash. Abbott said the deal will strengthen its...tional presence in the vascular business for polym...at keep blood vessels open.// Abbott has been the...
Other Medicine News:...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: